Zooming in on the Clinical Insights Exchange — Part 1
Earlier this month, Triall provided a product roadmap update introducing what we’ve dubbed the Clinical Insights Exchange (CIX), a federated data marketplace that will enable privacy-friendly reuse of clinical trial data and patient reimbursement through a combination of decentralised and privacy-enhancing technologies. In this article, we’ll zoom in on the targeted features and benefits of the CIX, our Self-Sovereign Identity (SSI) wallet, and the integration of our utility token TRL.
Article summary
- The CIX is a federated data marketplace that aims to provide a platform for advanced cryptographic techniques and AI models, allowing for privacy-friendly analysis over aggregated clinical trial datasets.
- Triall envisions TriallGPT, a chat agent that will enable even non-technical users to design compute jobs and obtain customer insights from CIX datasets.
- Triall’s SSI wallet will enable fine-grained, self-sovereign control over data assets and governing access permissions in the CIX.
- TRL will allow for new ownership models by providing a primary means of access, benefit-sharing, and reimbursement among all platform users.
Product spotlight
Introducing the CIX
More than 60,000 clinical trials are initiated each year, but collected data is often only used for the purpose of a single study due to lack of sharing infrastructure and incentives as well as confidentiality and privacy concerns. Clinical trial data therefore represents a vastly growing and largely untapped resource that offers a wealth of opportunities for advancing drug development globally. To illustrate, this data can be used to inform and improve future study designs, simulate clinical trial outcomes, and identify new drug targets — practices that have become more and more promising with the increasing maturity and adoption of AI.
The CIX aims to enable the reuse of clinical trial data by offering a federated data marketplace where biopharma professionals, clinicians, and patients can exchange clinical research data and insights without having to share or otherwise expose underlying data resources. It will interconnect existing eClinical software, health information, and other data hosting systems using a combination of decentralised and privacy-enhancing technologies, thereby facilitating the self-sovereign exchange and reuse of clinical trial data across currently siloed environments.
Applying advanced cryptographic techniques and AI models such as Compute-to-Data and secure Multi-Party Computation (MPC), Triall CIX will allow authorised parties to perform privacy-friendly analyses over datasets connected to the platform. Thus, it enables data providers, such as biopharma companies and medical research centres, to repurpose and create value from their sensitive research data without compromising data privacy or confidentiality.
👉 Our federated data ecosystem will empower data scientists and AI experts to design advanced data analytics services across aggregated data from multiple clinical trials and multiple host systems.
TriallGPT for navigating data assets and algorithms
Platform users will be able to search a federated catalogue of data assets and algorithms that fit their specific needs and requirements, filtering on properties such as therapeutic area, study phase, and geography. In addition to the catalogue, we foresee the release of a chat agent called TriallGPT (based on open-source Large Language Models) that guides and supports users in identifying and exploring relevant data assets, algorithms, and use cases. TriallGPT would enable even non-technical users to design compute jobs and obtain customer insights from CIX datasets. It therefore facilitates usability and adoption by enabling virtually any authorised user to interact with CIX datasets and conduct exploratory data analysis.
👉 As AI models become increasingly sophisticated, we envision TriallGPT to increasingly take the role of a remote data scientist, supporting platform users with designing, training, and validating algorithms.
SSI wallet for configuring access permissions
To enable biopharma companies, medical research centres, and other type of data providers to share their data, its paramount to ensure data security and access control. Since early 2022, Triall has therefore been developing a tamper-resistant and highly adaptable identity and access management (IAM) solution together with its partner Sphereon that leverages blockchain and Self-Sovereign Identity (SSI) standards. The solution comprises an SSI wallet mobile app that enables fine-grained, self-sovereign control over data assets and governing access permissions in the CIX. This ensures data providers have full control in defining the terms and conditions associated with data exchange (with whom, for which purposes, against which fees, etc.).
TRL for access, benefit-sharing, and reimbursement
Triall aims to promote fair and equitable sharing of benefits among all stakeholders involved in clinical research, and advocates sovereign patient data ownership and empowerment. Improving on patient centricity in this manner promises to benefit patient recruitment, retention, and engagement in clinical trials — something the industry has been struggling with for decades, contributing to high costs of conducting trials. The global transition to Web3, rise of the data economy, and a shifting regulatory landscape further underline this vision.
Triall CIX will offer a Web3 toolkit to empower, compensate, and incentivise data providers and participants (incl. patients and healthy volunteers) in engaging with the platform. Here, our platform-native utility tokens TRL and TCRED will provide a primary means of access, benefit-sharing, and reimbursement.
👉 Triall’s utility token TRL allows for automated reimbursement and new compensation models where patients can be reimbursed for the secondary use of their data contributions to a clinical trial.
Liked what you’re reading? In Part 2 and Part 3 of this series we will dive into different data use cases and our go-to-market strategy.
About Triall
Triall is a company that offers innovative software and supporting services to organisations involved in clinical trials. Since 2018, the company has been spearheading the implementation of decentralised and privacy-enhancing technologies for clinical research settings. Triall’s vision is to shape a digital ecosystem for clinical trials: a cross-system, multi-sided collaboration platform through which biopharma professionals, clinicians, patients, and other clinical trial stakeholders can collaborate and exchange research data and insights in a secure, verifiable, and self-sovereign way.
Check out our website: https://www.triall.io/
Follow us on Twitter: https://twitter.com/triallofficial
Join the discussion at: https://t.me/triallcommunity
